477P Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)

H.J Lenz,J Weberpals,C Cremolini,A Grothey,B Leutgeb,S Mahrus,H Nimeiri,I Reyes-Rivera,J Seligmann,J Tabernero,S Tejpar,T Yoshino,S Stintzing

doi:10.1016/j.annonc.2021.08.998

477P Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)

H.J Lenz, J Weberpals + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.998

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
License type: publisher-specific-oa

Affiliation: Roche (Switzerland), University of Pisa, West Cancer Center, Leeds Teaching Hospitals NHS Trust, Institut Català d'Oncologia, KU Leuven, National Cancer Center Hospital East, Charité - Universitätsmedizin Berlin

#1L Therapy #Microsatellite Instability + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In the last decade, molecular profiling in mCRC has become integral to informed treatment decision-making; however, up-to-date data on testing frequency are lacking. We aimed to describe the utilisation and factors correlated with testing for RAS, BRAF and microsatellite instability (MSI) testing prior to 1L therapy initiation in mCRC.

Full Text